Opinion|Videos|November 22, 2024
R/R MM: Bispecifics in R/R MM: Key Takeaways
Panelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is promoted by the following;
- What are your current strategies for managing AEs (skin toxicities, dysgeusia, etc) seen with talquetamab?
- When do these toxicities typically appear, and how often do you see them in practice?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, AE management) in R/R MM.
- What clinical pearls can you share for fellow medical oncologists considering the use of bispecifics in R/R MM?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5